



Ann Mullally

George E. Becker Professor in Medicine
Medicine - Hematology

CLINICAL OFFICE (PRIMARY)

- **Stanford Cancer Center**

875 Blake Wilbur Dr

Clinic A MC 6560

Stanford, CA 94305

Tel (650) 498-6000

Fax (650) 724-5203

Bio

BIO

Dr. Ann Mullally is a physician-scientist and Division Chief of Hematology. Her laboratory studies the genetics, biology and therapy of myeloid blood cancers, with a focus on myeloproliferative neoplasms (MPN). Using primary human samples, mouse models, genomics, single-cell sequencing and CRISPR, as well as cellular and molecular biology, the lab has investigated the key genetic events underlying MPN pathogenesis. Dr. Mullally's lab elucidated the mechanism by which mutant calreticulin (CALR) is oncogenic and causes MPN. The lab has also worked extensively on the JAK2V617F mutation, the molecular dependencies of MPN stem cells and the biology of myelofibrosis. Dr. Mullally received her MD from University College Dublin, completed residency at Johns Hopkins and fellowship in hematology/oncology in the Brigham/Mass General/Dana-Farber program. Prior to moving to Stanford in 2024, Dr. Mullally was a Principal Investigator at Brigham and Women's Hospital and a clinical faculty member at Dana-Farber Cancer Institute for approximately 10 years. Dr. Mullally is actively involved in all aspects of patient-oriented research. The overarching goal of her research is to advance the biological understanding of myeloid malignancies and to translate this into improved treatment options for patients dealing with these chronic blood cancers. Dr. Mullally is known as a passionate advocate for physician-scientists in medicine, for her outstanding mentorship of trainees and as a champion of collaborative team science.

CLINICAL FOCUS

- Hematology/Oncology
- Myeloproliferative Neoplasms

ACADEMIC APPOINTMENTS

- Professor, Medicine - Hematology
- Member, Bio-X
- Member, Stanford Cancer Institute

ADMINISTRATIVE APPOINTMENTS

- Chief, Division of Hematology, Stanford University, (2024- present)

HONORS AND AWARDS

- Member, American Society of Clinical Investigation, ASCI (2018)
- Scholar Award, Leukemia & Lymphoma Society (2017)
- Young Physician-Scientist Award, ASCI (2014)
- Clinical Investigator Award, Damon Runyon Cancer Research Foundation (2013)
- Scholar Award, American Society of Hematology (2010)

BOARDS, ADVISORY COMMITTEES, PROFESSIONAL ORGANIZATIONS

- Member, Stanford Cancer Institute (2024 - present)
- Scientific Advisory Board, MPN Research Foundation (2021 - present)
- Scientific Editor, Blood Cancer Discovery (2021 - present)
- Editorial Board Member, Blood (2018 - present)
- Member, American Society of Hematology (2005 - present)

PROFESSIONAL EDUCATION

- Board Certification: Hematology, American Board of Internal Medicine (2009)
- Fellowship: Dana Farber Cancer Institute Hematology Oncology Fellowship (2010) MA
- Residency: Johns Hopkins Hospital Internal Medicine Residency (2005) MD
- Medical Education: University College Dublin (1999) Ireland
- Board Certification, American Board of Internal Medicine , Hematology (2019)
- Fellowship, Harvard Medical School , Hematology/Oncology (2010)
- Residency, Johns Hopkins Hospital , Internal Medicine (2005)
- Medical Education, University College Dublin, Ireland , School of Medicine (1999)

LINKS

- Mullally Lab: <https://mullallylab.stanford.edu/>
- LinkedIn Profile: https://www.linkedin.com/in/ann-mullally-2aa5772b?utm_source=share_via&utm_content=profile&utm_medium=member_ios
- Bluesky: <https://bsky.app/profile/mullallylab.bsky.social>

Research & Scholarship

CURRENT RESEARCH AND SCHOLARLY INTERESTS

Myeloproliferative neoplasms (MPN) are chronic blood cancers that arise in the hematopoietic stem cell compartment, have a long pre-clinical phase (termed clonal hematopoiesis) and an intrinsic risk of progression to related myeloid malignancies, including to acute myeloid leukemia (AML).

Although the key genetic driver mutations that cause MPN have been identified, we are currently lacking curative medical therapies to target these. Our laboratory is interested in all aspects of disease biology from pre-clinical to advanced phase MPN. Some active areas of research include: (i) biology and immunological targeting of mutant calreticulin, (ii) elucidating factors that constrain and promote expansion of JAK2-mutant MPN stem cells, (iii) targeting JAK2V617F clonal hematopoiesis to prevent MPN, (iv) mutational agnostic approaches to target advanced phase MPN, (v) CRISPR gene editing in MPN.

Teaching

STANFORD ADVISEES

Doctoral Dissertation Reader (AC)

James Chavez, Freja Ekman

Postdoctoral Faculty Sponsor

Maximilian Englert, Christian Hackenbroch, Benjamin Rolles

Doctoral Dissertation Advisor (AC)

Mattias de los Rios Rogers

Postdoctoral Research Mentor

Gangpyo Ryu

Publications

PUBLICATIONS

- **Mutant SRSF2-associated impaired erythropoiesis is defined by increased mTORC1 signaling due to FYN missplicing.** *Leukemia*
Jutzi, J. S., Crosse, E., Kim, C. J., van Gasteren, B., Laurore, C., Rolles, B., Kramer, F., Tishena, A., Rocha, A. V., Wazir, M., Weeks, L. D., How, J., Stahl, et al
2026
- **Risk stratification of patients with TP53-mutated myeloproliferative neoplasms.** *Leukemia*
Rolles, B., Filho, C. i., Fergusson, N., Bewersdorf, J. P., Keating, J., Perkins, C., Schwede, M., England, J., Luskin, M. R., DeAngelo, D. J., Shimony, S., Faiz, M., Hillerbrand, et al
2026
- **ZRSR2 loss causes aberrant splicing in JAK2V617F-driven myeloproliferative neoplasm but is not sufficient to drive disease progression.** *HemaSphere*
Zhang, R., Straube, J., Janardhanan, Y., Haldar, R., Cooper, L., Hayes, N., Laurore, C., Kim, C. J., Luskin, M. R., Lindsley, R. C., Stahl, M., Mullally, A., Marneth, et al
2025; 9 (9): e70225
- **Novel Strategies Targeting Mutant Calreticulin in Essential Thrombocythemia and Myelofibrosis.** *Blood*
Salzman, G. S., Mullally, A.
2025
- **Mutant Calreticulin in MPN: Mechanistic Insights and Therapeutic Implications.** *Current hematologic malignancy reports*
Faiz, M., Riedemann, M., Jutzi, J. S., Mullally, A.
2025; 20 (1): 4
- **Evolution of myeloproliferative neoplasms from normal blood stem cells.** *Haematologica*
Hormoz, S., Sankaran, V. G., Mullally, A.
2024
- **Trial-in-Progress: A Phase 2 Study of Ruxolitinib in Low-Risk Essential Thrombocythemia and Polycythemia Vera Patients with High Symptom Burden**
How, C., Liu, Y., Gallagher, K., Logan, E. K., Mullally, A., Neuberg, D. S., Reardon, T., Watson, A., Deangelo, D. J., Patell, R., Hobbs, G. S.
ELSEVIER.2024: 6644-6645
- **Mutation-Specific Differences in the Relationship between Obesity and Clonal Hematopoiesis, with a Focus on <i>JAK2^{V617F}</i> and MPN Prevention**
Rolles, B., Sekar, A., Serrano-Ron, L., Faiz, N., Perry, A., Hillerbrandt, A., Hem, J., Jutzi, J., Marneth, A. E., Niroula, A., Bick, A. G., Gibson, C. J., Griffin, et al
ELSEVIER.2024: 872-873

- **Antibody targeting of mutant calreticulin in myeloproliferative neoplasms.** *Journal of cellular and molecular medicine*
Kramer, F., Mullally, A.
2023; 28 (5): e17896
- **Biology and therapeutic targeting of molecular mechanisms in MPNs.** *Blood*
How, J., Garcia, J. S., Mullally, A.
2023; 141 (16): 1922-1933
- **CALR-mutated cells are vulnerable to combined inhibition of the proteasome and the endoplasmic reticulum stress response.** *Leukemia*
Jutzi, J. S., Marneth, A. E., Jiménez-Santos, M. J., Hem, J., Guerra-Moreno, A., Rolles, B., Bhatt, S., Myers, S. A., Carr, S. A., Hong, Y., Pozdnyakova, O., van Galen, P., Al-Shahrour, et al
2023; 37 (2): 359-369
- **Two to tango! IL-13 and TGF- β drive myelofibrosis.** *Blood*
Jutzi, J. S., Mullally, A.
2022; 140 (26): 2767-2768
- **Molecular Pathogenesis of Myeloproliferative Neoplasms.** *Current hematologic malignancy reports*
Rolles, B., Mullally, A.
2022; 17 (6): 319-329
- **Mechanical checkpoint regulates monocyte differentiation in fibrotic niches.** *Nature materials*
Vining, K. H., Marneth, A. E., Adu-Berchie, K., Grolman, J. M., Tringides, C. M., Liu, Y., Wong, W. J., Pozdnyakova, O., Severgnini, M., Stafford, A., Duda, G. N., Hodi, F. S., Mullally, et al
2022; 21 (8): 939-950
- **Whole-genome CRISPR screening identifies N-glycosylation as a genetic and therapeutic vulnerability in CALR-mutant MPN.** *Blood*
Jutzi, J. S., Marneth, A. E., Ciboddo, M., Guerra-Moreno, A., Jiménez-Santos, M. J., Kosmidou, A., Dressman, J. W., Liang, H., Hamel, R. S., Lozano, P. R., Rumi, E., Doench, J., Gotlib, et al
2022
- **Calreticulin mutant myeloproliferative neoplasms induce MHC-I skewing, which can be overcome by an optimized peptide cancer vaccine.** *Science translational medicine*
Gigoux, M., Holmström, M. O., Zappasodi, R., Park, J. J., Pourpe, S., Bozkus, C. C., Mangarin, L. M., Redmond, D., Verma, S., Schad, S., George, M. M., Venkatesh, D., Ghosh, et al
2022; 14 (649): eaba4380
- **Genomic profiling of a randomized trial of interferon- α vs hydroxyurea in MPN reveals mutation-specific responses.** *Blood advances*
Knudsen, T. A., Skov, V., Stevenson, K., Werner, L., Duke, W., Laureore, C., Gibson, C. J., Nag, A., Thorner, A. R., Wollison, B., Hansen, D. L., Ellervik, C., El Fassi, et al
2022; 6 (7): 2107-2119
- **Transcriptional differences between JAK2-V617F and wild-type bone marrow cells in patients with myeloproliferative neoplasms.** *Experimental hematology*
Van Egeren, D., Kamaz, B., Liu, S., Nguyen, M., Reilly, C. R., Kalyva, M., DeAngelo, D. J., Galinsky, I., Wadleigh, M., Winer, E. S., Luskin, M. R., Stone, R. M., Garcia, et al
2022; 107: 14-19
- **Suppression of multiple anti-apoptotic BCL2 family proteins recapitulates the effects of JAK2 inhibitors in JAK2V617F driven myeloproliferative neoplasms.** *Cancer science*
Takei, H., Coelho-Silva, J. L., Tavares Leal, C., Queiroz Arantes Rocha, A., Mantello Bianco, T., Welner, R. S., Mishima, Y., Kobayashi, I. S., Mullally, A., Lima, K., Machado-Neto, J. A., Kobayashi, S. S., Lobo de Figueiredo-Pontes, et al
2022; 113 (2): 597-608
- **Hydroxycarbamide effects on DNA methylation and gene expression in myeloproliferative neoplasms.** *Genome research*
Contreras Castillo, S., Montibus, B., Rocha, A., Duke, W., von Meyenn, F., McLornan, D., Harrison, C., Mullally, A., Schulz, R., Oakey, R. J.
2021; 31 (8): 1381-1394
- **Zinc-dependent multimerization of mutant calreticulin is required for MPL binding and MPN pathogenesis.** *Blood advances*
Rivera, J. F., Baral, A. J., Nadat, F., Boyd, G., Smyth, R., Patel, H., Burman, E. L., Alameer, G., Boxall, S. A., Jackson, B. R., Baxter, E. J., Laslo, P., Green, et al

2021; 5 (7): 1922-1932

- **Reconstructing the Lineage Histories and Differentiation Trajectories of Individual Cancer Cells in Myeloproliferative Neoplasms.** *Cell stem cell*
Van Egeren, D., Escabi, J., Nguyen, M., Liu, S., Reilly, C. R., Patel, S., Kamaz, B., Kalyva, M., DeAngelo, D. J., Galinsky, I., Wadleigh, M., Winer, E. S., Luskin, et al
2021; 28 (3): 514-523.e9
- **COVID-19 and myeloproliferative neoplasms: some considerations.** *Leukemia*
Kamaz, B., Mullally, A.
2021; 35 (1): 279-281
- **Splicing factor YBX1 mediates persistence of JAK2-mutated neoplasms.** *Nature*
Jayavelu, A. K., Schnöder, T. M., Perner, F., Herzog, C., Meiler, A., Krishnamoorthy, G., Huber, N., Mohr, J., Edelmann-Stephan, B., Austin, R., Brandt, S., Palandri, F., Schröder, et al
2020; 588 (7836): 157-163
- **Pregnancy outcomes, risk factors, and cell count trends in pregnant women with essential thrombocythemia.** *Leukemia research*
How, J., Leiva, O., Bogue, T., Fell, G. G., Bustoros, M. W., Connell, N. T., Connors, J. M., Ghobrial, I. M., Kuter, D. J., Mullally, A., Neuberger, D., Zwicker, J. I., Fogerty, et al
2020; 98: 106459
- **Augmenting emergency granulopoiesis with CpG conditioned mesenchymal stromal cells in murine neutropenic sepsis.** *Blood advances*
Ng, J., Guo, F., Marneth, A. E., Ghanta, S., Kwon, M. Y., Keegan, J., Liu, X., Wright, K. T., Kamaz, B., Cahill, L. A., Mullally, A., Perrella, M. A., Lederer, et al
2020; 4 (19): 4965-4979
- **Remodeling the Bone Marrow Microenvironment - A Proposal for Targeting Pro-inflammatory Contributors in MPN.** *Frontiers in immunology*
Jutzi, J. S., Mullally, A.
2020; 11: 2093
- **Murine Models of Myelofibrosis.** *Cancers*
Jacquelin, S., Kramer, F., Mullally, A., Lane, S. W.
2020; 12 (9)
- **Busy signal: platelet-derived growth factor activation in myelofibrosis.** *Haematologica*
Marneth, A. E., Mullally, A.
2020; 105 (8): 1988-1990
- **Fedratinib in myelofibrosis.** *Blood advances*
Mullally, A., Hood, J., Harrison, C., Mesa, R.
2020; 4 (8): 1792-1800
- **Distinct effects of ruxolitinib and interferon-alpha on murine JAK2V617F myeloproliferative neoplasm hematopoietic stem cell populations.** *Leukemia*
Austin, R. J., Straube, J., Bruedigam, C., Pali, G., Jacquelin, S., Vu, T., Green, J., Gräsel, J., Lansink, L., Cooper, L., Lee, S. J., Chen, N. T., Lee, et al
2020; 34 (4): 1075-1089
- **The Molecular Genetics of Myeloproliferative Neoplasms.** *Cold Spring Harbor perspectives in medicine*
Marneth, A. E., Mullally, A.
2020; 10 (2)
- **Both sides now: losses and gains of mutant CALR.** *Blood*
Mullally, A.
2020; 135 (2): 82-83
- **Mutant calreticulin in myeloproliferative neoplasms.** *Blood*
How, J., Hobbs, G. S., Mullally, A.
2019; 134 (25): 2242-2248
- **The kinases IKBKE and TBK1 regulate MYC-dependent survival pathways through YB-1 in AML and are targets for therapy.** *Blood advances*

- Liu, S., Marneth, A. E., Alexe, G., Walker, S. R., Gandler, H. I., Ye, D. Q., Labella, K., Mathur, R., Toniolo, P. A., Tillgren, M., Gokhale, P. C., Barbie, D., Mullally, et al
2018; 2 (23): 3428-3442
- **JAK2 (and other genes) be nimble with MPN diagnosis, prognosis, and therapy.** *Hematology. American Society of Hematology. Education Program*
Ciboddo, M., Mullally, A.
2018; 2018 (1): 110-117
 - **Gli1+ Mesenchymal Stromal Cells Are a Key Driver of Bone Marrow Fibrosis and an Important Cellular Therapeutic Target.** *Cell stem cell*
Schneider, R. K., Mullally, A., Dugourd, A., Peisker, F., Hoogenboezem, R., Van Strien, P. M., Bindels, E. M., Heckl, D., Büsche, G., Fleck, D., Müller-Newen, G., Wongboonsin, J., Ventura Ferreira, et al
2018; 23 (2): 308-309
 - **Increased neutrophil extracellular trap formation promotes thrombosis in myeloproliferative neoplasms.** *Science translational medicine*
Wolach, O., Sellar, R. S., Martinod, K., Cherpokova, D., McConkey, M., Chappell, R. J., Silver, A. J., Adams, D., Castellano, C. A., Schneider, R. K., Padera, R. F., DeAngelo, D. J., Wadleigh, et al
2018; 10 (436)
 - **Defining the requirements for the pathogenic interaction between mutant calreticulin and MPL in MPN.** *Blood*
Elf, S., Abdelfattah, N. S., Baral, A. J., Beeson, D., Rivera, J. F., Ko, A., Florescu, N., Birrane, G., Chen, E., Mullally, A.
2018; 131 (7): 782-786
 - **JAK2, CALR, MPL and ASXL1 mutational status correlates with distinct histological features in Philadelphia chromosome-negative myeloproliferative neoplasms.** *Haematologica*
Wong, W. J., Hasserjian, R. P., Pinkus, G. S., Breyfogle, L. J., Mullally, A., Pozdnyakova, O.
2018; 103 (2): e63-e68
 - **Using CRISPR/Cas9 Gene Editing to Investigate the Oncogenic Activity of Mutant Calreticulin in Cytokine Dependent Hematopoietic Cells.** *Journal of visualized experiments : JoVE*
Abdelfattah, N. S., Mullally, A.
2018
 - **Kinase Inhibitors in the Treatment of Myeloid Malignancies.** *Hematology/oncology clinics of North America*
Mullally, A.
2017; 31 (4): ix-x
 - **The Development and Use of Janus Kinase 2 Inhibitors for the Treatment of Myeloproliferative Neoplasms.** *Hematology/oncology clinics of North America*
Hobbs, G. S., Rozelle, S., Mullally, A.
2017; 31 (4): 613-626
 - **Gli1+ Mesenchymal Stromal Cells Are a Key Driver of Bone Marrow Fibrosis and an Important Cellular Therapeutic Target.** *Cell stem cell*
Schneider, R. K., Mullally, A., Dugourd, A., Peisker, F., Hoogenboezem, R., Van Strien, P. M., Bindels, E. M., Heckl, D., Büsche, G., Fleck, D., Müller-Newen, G., Wongboonsin, J., Ventura Ferreira, et al
2017; 20 (6): 785-800.e8
 - **Gain of function in Jak2V617F-positive T-cells.** *Leukemia*
Nishanth, G., Wolleschak, D., Fahldieck, C., Fischer, T., Mullally, A., Perner, F., Schnöder, T. M., Just, S., Heidel, F. H., Schlüter, D.
2017; 31 (4): 1000-1003
 - **Myeloproliferative neoplasm stem cells.** *Blood*
Mead, A. J., Mullally, A.
2017; 129 (12): 1607-1616
 - **Underlying mechanisms of the JAK2V617F mutation in the pathogenesis of myeloproliferative neoplasms.** *Der Pathologe*
Mullally, A.
2016; 37 (Suppl 2): 175-179
 - **Physiologic Expression of Sf3b1(K700E) Causes Impaired Erythropoiesis, Aberrant Splicing, and Sensitivity to Therapeutic Spliceosome Modulation.** *Cancer cell*

- Obeng, E. A., Chappell, R. J., Seiler, M., Chen, M. C., Campagna, D. R., Schmidt, P. J., Schneider, R. K., Lord, A. M., Wang, L., Gambe, R. G., McConkey, M. E., Ali, A. M., Raza, et al
2016; 30 (3): 404-417
- **Mutant Calreticulin Requires Both Its Mutant C-terminus and the Thrombopoietin Receptor for Oncogenic Transformation.** *Cancer discovery*
Elf, S., Abdelfattah, N. S., Chen, E., Perales-Patón, J., Rosen, E. A., Ko, A., Peisker, F., Florescu, N., Giannini, S., Wolach, O., Morgan, E. A., Tothova, Z., Losman, et al
2016; 6 (4): 368-81
 - **Haemophagocytic lymphohistiocytosis in adults: a multicentre case series over 7 years.** *British journal of haematology*
Schram, A. M., Comstock, P., Campo, M., Gorovets, D., Mullally, A., Bodio, K., Arnason, J., Berliner, N.
2016; 172 (3): 412-9
 - **RECQL5 Suppresses Oncogenic JAK2-Induced Replication Stress and Genomic Instability.** *Cell reports*
Chen, E., Ahn, J. S., Sykes, D. B., Breyfogle, L. J., Godfrey, A. L., Nangalia, J., Ko, A., DeAngelo, D. J., Green, A. R., Mullally, A.
2015; 13 (11): 2345-2352
 - **Targeting megakaryocytic-induced fibrosis in myeloproliferative neoplasms by AURKA inhibition.** *Nature medicine*
Wen, Q. J., Yang, Q., Goldenson, B., Malinge, S., Lasho, T., Schneider, R. K., Breyfogle, L. J., Schultz, R., Gilles, L., Koppikar, P., Abdel-Wahab, O., Pardanani, A., Stein, et al
2015; 21 (12): 1473-80
 - **Role of the clathrin adaptor PICALM in normal hematopoiesis and polycythemia vera pathophysiology.** *Haematologica*
Ishikawa, Y., Maeda, M., Pasham, M., Aguet, F., Tacheva-Grigorova, S. K., Masuda, T., Yi, H., Lee, S. U., Xu, J., Teruya-Feldstein, J., Ericsson, M., Mullally, A., Heuser, et al
2015; 100 (4): 439-51
 - **Marked hyperferritinemia does not predict for HLH in the adult population.** *Blood*
Schram, A. M., Campigotto, F., Mullally, A., Fogerty, A., Massarotti, E., Neuberg, D., Berliner, N.
2015; 125 (10): 1548-52
 - **Dynamin 2-dependent endocytosis is required for normal megakaryocyte development in mice.** *Blood*
Bender, M., Giannini, S., Grozovsky, R., Jönsson, T., Christensen, H., Pluthero, F. G., Ko, A., Mullally, A., Kahr, W. H., Hoffmeister, K. M., Falet, H.
2015; 125 (6): 1014-24
 - **Distinct effects of concomitant Jak2V617F expression and Tet2 loss in mice promote disease progression in myeloproliferative neoplasms.** *Blood*
Chen, E., Schneider, R. K., Breyfogle, L. J., Rosen, E. A., Poveromo, L., Elf, S., Ko, A., Brumme, K., Levine, R., Ebert, B. L., Mullally, A.
2015; 125 (2): 327-35
 - **How does JAK2V617F contribute to the pathogenesis of myeloproliferative neoplasms?** *Hematology. American Society of Hematology. Education Program*
Chen, E., Mullally, A.
2014; 2014 (1): 268-76
 - **Hit the spleen, JAK!** *Blood*
Lane, S. W., Mullally, A.
2014; 124 (19): 2898-900
 - **JAK2V617F promotes replication fork stalling with disease-restricted impairment of the intra-S checkpoint response.** *Proceedings of the National Academy of Sciences of the United States of America*
Chen, E., Ahn, J. S., Massie, C. E., Clynes, D., Godfrey, A. L., Li, J., Park, H. J., Nangalia, J., Silber, Y., Mullally, A., Gibbons, R. J., Green, A. R.
2014; 111 (42): 15190-5
 - **Role of casein kinase 1A1 in the biology and targeted therapy of del(5q) MDS.** *Cancer cell*
Schneider, R. K., Ademà, V., Heckl, D., Järås, M., Mallo, M., Lord, A. M., Chu, L. P., McConkey, M. E., Kramann, R., Mullally, A., Bejar, R., Solé, F., Ebert, et al
2014; 26 (4): 509-20
 - **Loss of function of TET2 cooperates with constitutively active KIT in murine and human models of mastocytosis.** *PLoS one*

- De Vita, S., Schneider, R. K., Garcia, M., Wood, J., Gavillet, M., Ebert, B. L., Gerbaulet, A., Roers, A., Levine, R. L., Mullally, A., Williams, D. A. 2014; 9 (5): e96209
- **Csnk1a1 inhibition has p53-dependent therapeutic efficacy in acute myeloid leukemia.** *The Journal of experimental medicine*
Järås, M., Miller, P. G., Chu, L. P., Puram, R. V., Fink, E. C., Schneider, R. K., Al-Shahrour, F., Peña, P., Breyfogle, L. J., Hartwell, K. A., McConkey, M. E., Cowley, G. S., Root, et al
2014; 211 (4): 605-12
 - **Sinister symbiosis: pathological hematopoietic-stromal interactions in CML.** *Cell stem cell*
Mullally, A., Ebert, B. L.
2013; 13 (3): 257-8
 - **Depletion of Jak2V617F myeloproliferative neoplasm-propagating stem cells by interferon- α in a murine model of polycythemia vera.** *Blood*
Mullally, A., Bruedigam, C., Poveromo, L., Heidel, F. H., Purdon, A., Vu, T., Austin, R., Heckl, D., Breyfogle, L. J., Kuhn, C. P., Kalaitzidis, D., Armstrong, S. A., Williams, et al
2013; 121 (18): 3692-702
 - **miR-433 is aberrantly expressed in myeloproliferative neoplasms and suppresses hematopoietic cell growth and differentiation.** *Leukemia*
Lin, X., Rice, K. L., Buzzai, M., Hexner, E., Costa, F. F., Kilpivaara, O., Mullally, A., Soares, M. B., Ebert, B. L., Levine, R., Licht, J. D.
2013; 27 (2): 344-52
 - **Myeloproliferative neoplasm animal models.** *Hematology/oncology clinics of North America*
Mullally, A., Lane, S. W., Brumme, K., Ebert, B. L.
2012; 26 (5): 1065-81
 - **Heterodimeric JAK-STAT activation as a mechanism of persistence to JAK2 inhibitor therapy** *NATURE*
Koppikar, P., Bhagwat, N., Kilpivaara, O., Manshour, T., Adli, M., Hricik, T., Liu, F., Saunders, L. M., Mullally, A., Abdel-Wahab, O., Leung, L., Weinstein, A., Marubayashi, et al
2012; 489 (7414): 155-U222
 - **Distinct roles for long-term hematopoietic stem cells and erythroid precursor cells in a murine model of Jak2V617F-mediated polycythemia vera.** *Blood*
Mullally, A., Poveromo, L., Schneider, R. K., Al-Shahrour, F., Lane, S. W., Ebert, B. L.
2012; 120 (1): 166-72
 - **EXEL-8232, a small-molecule JAK2 inhibitor, effectively treats thrombocytosis and extramedullary hematopoiesis in a murine model of myeloproliferative neoplasm induced by MPLW515L** *LEUKEMIA*
Wernig, G., Kharas, M. G., Mullally, A., Leeman, D. S., Okabe, R., George, T., Clary, D. O., Gilliland, D. G.
2012; 26 (4): 720-727
 - **Coordinate loss of a microRNA and protein-coding gene cooperate in the pathogenesis of 5q(-) syndrome** *BLOOD*
Kumar, M. S., Narla, A., Nonami, A., Mullally, A., Dimitrova, N., Ball, B., McAuley, J. R., Poveromo, L., Kutok, J. L., Galili, N., Raza, A., Attar, E., Gilliland, et al
2011; 118 (17): 4666-4673
 - **Haploinsufficiency for ribosomal protein genes causes selective activation of p53 in human erythroid progenitor cells** *BLOOD*
Dutt, S., Narla, A., Lin, K., Mullally, A., Abayasekara, N., Megerdichian, C., Wilson, F. H., Currie, T., Khanna-Gupta, A., Berliner, N., Kutok, J. L., Ebert, B. L.
2011; 117 (9): 2567-2576
 - **Mutations with epigenetic effects in myeloproliferative neoplasms and recent progress in treatment: Proceedings from the 5th International Post-ASH Symposium** *BLOOD CANCER JOURNAL*
Tefferi, A., Abdel-Wahab, O., Cervantes, F., Crispino, J. D., Finazzi, G., Girodon, F., Gisslinger, H., Gotlib, J., Kiladjian, J., Levine, R. L., Licht, J. D., Mullally, A., Odenike, et al
2011; 1
 - **STATistical power of clonal analysis: differential STAT1 pathway activation downstream of the JAK2V617F mutation.** *Cancer cell*
Mullally, A., Ebert, B. L.
2010; 18 (5): 405-6
 - **CNS relapse in acute promyelocytic leukemia.** *Journal of clinical oncology : official journal of the American Society of Clinical Oncology*

- Housman, E., Chang, P., Lane, S. W., Blinder, R., Galinsky, I., Kesari, S., Ho, V. T., Stone, R. M., Mullally, A.
2010; 28 (24): e409-11
- **NF1 inactivation revs up Ras in adult acute myelogenous leukemia.** *Clinical cancer research : an official journal of the American Association for Cancer Research*
Mullally, A., Ebert, B. L.
2010; 16 (16): 4074-6
 - **Physiological Jak2V617F Expression Causes a Lethal Myeloproliferative Neoplasm with Differential Effects on Hematopoietic Stem and Progenitor Cells** *CANCER CELL*
Mullally, A., Lane, S. W., Ball, B., Megerdichian, C., Okabe, R., Al-Shahrour, F., Paktinat, M., Haydu, J. E., Housman, E., Lord, A. M., Wernig, G., Kharas, M. G., Mercher, et al
2010; 17 (6): 584-596
 - **Frequent TET2 mutations in systemic mastocytosis: clinical, KITD816V and FIP1L1-PDGFRα correlates.** *Leukemia*
Tefferi, A., Levine, R. L., Lim, K. H., Abdel-Wahab, O., Lasho, T. L., Patel, J., Finke, C. M., Mullally, A., Li, C. Y., Pardanani, A., Gilliland, D. G.
2009; 23 (5): 900-4
 - **TET2 mutations and their clinical correlates in polycythemia vera, essential thrombocythemia and myelofibrosis.** *Leukemia*
Tefferi, A., Pardanani, A., Lim, K. H., Abdel-Wahab, O., Lasho, T. L., Patel, J., Gangat, N., Finke, C. M., Schwager, S., Mullally, A., Li, C. Y., Hanson, C. A., Mesa, et al
2009; 23 (5): 905-11
 - **A germline JAK2 SNP is associated with predisposition to the development of JAK2(V617F)-positive myeloproliferative neoplasms.** *Nature genetics*
Kilpivaara, O., Mukherjee, S., Schram, A. M., Wadleigh, M., Mullally, A., Ebert, B. L., Bass, A., Marubayashi, S., Heguy, A., Garcia-Manero, G., Kantarjian, H., Offit, K., Stone, et al
2009; 41 (4): 455-9
 - **Beyond HLA: the significance of genomic variation for allogeneic hematopoietic stem cell transplantation.** *Blood*
Mullally, A., Ritz, J.
2007; 109 (4): 1355-62
 - **Wasted sheep and premature infants: the role of trace metals in hematopoiesis.** *Blood reviews*
Mullally, A. M., Vogelsang, G. B., Moliterno, A. R.
2004; 18 (4): 227-34